Prostate cancer (PCa) is one of the most prevalent cancers in men worldwide, and hormonal
therapy plays a key role in the treatment of PCa. However, the drug resistance of hormonal …

Prostate cancer (PCa) seriously threatens male health, and targeting dual-specificity
tyrosine phosphorylation-regulated kinase 2 (DYRK2) has been verified to reduce PCa …

Prostate cancer (PCa) is a common male cancer with high incidence and mortality, and
hormonal therapy as the major treatment for PCa patients is troubled by the inevitable …

Abstract NKX3. 1 is a prostate-specific homeodomain protein and tumor suppressor whose
expression is reduced in the earliest phases of prostatic neoplasia. NKX3. 1 expression is …

Metastatic cancer remains incurable as patients eventually loose sensitivity to targeted
therapies and chemotherapies, further leading to poor clinical outcome. Thus, there is a …

The kinase DYRK1A is an attractive target for drug discovery programs due to its implication
in multiple diseases. Through a fragment screen, we identified a simple biaryl compound …

Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is an evolutionarily
conserved protein kinase and the most studied member of the Dual-specificity tyrosine …

Background and aims Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive
tumour with a poor prognosis using current treatments. Targeted therapies may offer a new …

The dual-specificity tyrosine phosphorylation-regulated kinase DYRK2 has emerged as a
critical regulator of cellular processes. We took a chemical biology approach to gain further …

Members of the dual-specificity tyrosine-regulated kinase (DYRKs) subfamily possess a
distinctive capacity to phosphorylate tyrosine, serine, and threonine residues. Among the …